Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer - Concepedia

Concepedia

Publication | Open Access

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

DOI Full Paper Access

111

Citations

40

References

2021

Year

Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar Latif, János L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarrin,

Gynecologic Oncology

References

	Year	Citations

Page 1